整合 CD28、4-1BB 和 CD27 的三重共刺激 GD2-CAR-T 细胞在实体瘤模型中介导强效细胞毒性并减少耗竭

Triple-costimulatory GD2-CAR T cells incorporating CD28, 4-1BB and CD27 mediate potent cytotoxicity and reduce exhaustion in solid tumour models.

FECH：影响 CAR-T 细胞表型与功能的新型代谢靶点

FECH, a novel metabolic target influencing CAR T-cell phenotype and function.

精准医学在神经母细胞瘤中的作用：靶向治疗与个体化方法——叙述性综述

The Role of Precision Medicine in Neuroblastoma: Targeted Therapies and Personalized Approaches-A Narrative Review.

精准医学通过提高诊断特异性和治疗效果并降低毒性，改变了神经母细胞瘤的治疗。在新兴策略中，ALK 靶向治疗和抗 GD2 免疫治疗显示出强大的临床潜力，尽管仍需进一步验证以改善患病儿童的生存率和生活质量。

EZH2 抑制剂他泽司他（tazemetostat）在尤因肉瘤中模型依赖性的 GD2 上调：与 GD2 特异性 CAR-T 细胞联合的前提条件

Model-dependent GD2 upregulation in Ewing sarcoma with the EZH2 inhibitor tazemetostat: Prerequisites for combination with GD2-specific CAR T cells.

放射性药物通过肿瘤增敏与肿瘤微环境重塑增强 CAR-T 细胞对放射敏感及放射抵抗神经母细胞瘤的作用

A radiopharmaceutical enhances CAR T cells against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and TME remodeling.

免疫治疗在神经母细胞瘤治疗中的作用

The role of immunotherapy in the treatment of neuroblastoma.

优化儿童肿瘤学中的疗效-毒性范式：免疫治疗与生存结局的叙述性综述

Optimizing the Efficacy-Toxicity Paradigm in Pediatric Oncology: A Narrative Review of Immunotherapy and Survivorship Outcomes.

免疫治疗改变了结局，但时机至关重要，因为更早应用可显著改善生存。

靶向 GD2 的 CAR-T 细胞治疗神经母细胞瘤：进展、挑战与未来展望

Targeting GD2 with CAR-T Cell Therapy in Neuroblastoma: Updates, Challenges, and Future Perspectives.

儿童实体瘤免疫治疗：通过合理的多模式联合克服生物学屏障

Immunotherapy for pediatric solid tumors: overcoming biological barriers through rational multimodal combinations.

I 类 HDAC 抑制增强 CRISPR 工程化 CAR-T 细胞在神经母细胞瘤中的干细胞样记忆特性

Class I HDAC inhibition enhances the stem-like memory properties of CRISPR-engineered CAR T cells in neuroblastoma.